{"entity":{"id":"danny-rischin","kind":"person","name":"Danny Rischin","aka":[],"tldr":"Melbourne oncologist who led C-POST, the trial that showed cemiplimab after surgery and radiotherapy cuts recurrence in high-risk cutaneous squamous-cell carcinoma.","summary":"Danny Rischin directs medical oncology at the Peter MacCallum Cancer Centre and chairs head and neck trials for the Trans-Tasman Radiation Oncology Group. He was first author of the 2025 New England Journal of Medicine report of C-POST, in which adjuvant cemiplimab improved disease-free survival compared with placebo after surgery and radiotherapy for high-risk cutaneous squamous-cell carcinoma, and led the cemiplimab phase 2 programme in advanced disease.","asOf":"2026-09-18","links":[],"tags":["skin","head-and-neck","immunotherapy","trialist"],"related":[],"cancers":["advanced-cutaneous-scc","head-and-neck","skin-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["peter-mac"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-c-post-adjuvant-cemiplimab-nejm-2025"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist and Director of Medical Oncology, Peter MacCallum Cancer Centre","institutionId":"peter-mac","specialisms":["Head and neck cancer","Cutaneous squamous-cell carcinoma","Chemoradiotherapy trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rischin%5BAuthor%5D"}],"papers":[],"orcid":"0000-0002-3368-0386"},"route":"/people/danny-rischin/","neighbours":{"cancer":[{"id":"advanced-cutaneous-scc","kind":"cancer","name":"Advanced cutaneous squamous cell carcinoma","route":"/cancers/advanced-cutaneous-scc/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/"}],"institution":[{"id":"peter-mac","kind":"institution","name":"Peter MacCallum Cancer Centre","route":"/institutions/peter-mac/"}],"paper":[{"id":"paper-c-post-adjuvant-cemiplimab-nejm-2025","kind":"paper","name":"C-POST: adjuvant cemiplimab versus placebo in high-risk cutaneous squamous cell carcinoma","route":"/key-papers/paper-c-post-adjuvant-cemiplimab-nejm-2025/"}]}}